393 Results
Sort By:
Published on October 23, 2024
A healthy diet may reduce the chance of low risk prostate cancer progressing in men undergoing active surveillance, according to a team led by researchers at Johns Hopkins Medicine. This finding further supports the idea that men with lower risk prostate cancer can be carefully monitored in lieu of undergoing…
Published on October 9, 2024
A blood test that measures the number of circulating tumor cells (CTCs) at the time of metastatic prostate cancer diagnosis can predict treatment response, disease progression, and overall survival, regardless of subsequent therapies over time, shows a study led by University of Southern California (USC) researchers. The test could be…
Published on October 3, 2024
The question of whose DNA or RNA was used to develop a complex genetic test, such as those that use AI to identify patterns of genetic variants or gene expression levels, is fundamental to its applicability—the people most like those who were used to develop the test are the most…
Published on September 25, 2024
A preclinical mouse model that uses CRISPR reveals how prostate cancer spreads or metastasizes. The model developed by a team of researchers led by Weill Cornell Medicine demonstrates the routes prostate cancer metastatic cells take as they travel through the body, and could lead to more effective treatments. Their findings…
Published on September 16, 2024
Men with a specific prostate cancer mutation could benefit from treatment with dual immunotherapy with immune checkpoint inhibitors. Writing in the Annals of Oncology, Niven Mehra, MD, PhD, an oncologist and researcher based at the Radboud University Medical Center in the Netherlands, and colleagues report that men whose tumor had…
Published on September 11, 2024
New research from the University of Michigan has shed light on a pivotal protein, NSD2, and its role in promoting prostate cancer. NSD2 is a histone methyltransferase, a protein responsible for modifying histones—proteins around which DNA is wrapped. This modification influences the accessibility of DNA, ultimately affecting gene expression. In…
Published on September 5, 2024
Widespread, opportunistic testing for prostate specific antigen (PSA) could be contributing the overdiagnosis of prostate cancer across Europe, researchers warn. Their findings, in The BMJ, have implications for prostate cancer screening programs and initiatives such as Europe’s Beating Cancer Plan. This EU project recently released recommendations from European Commission’s council…
Published on September 4, 2024
Data from a team of Australian researchers shows the potential of a new therapeutic strategy for treating castration-resistant prostate cancer (CRPC), the most aggressive form of the disease. The research, published in the British Journal of Cancer, studied the role of Cyclin-Dependent Kinase 9 (CDK9) in the progression of aggressive…
Published on August 28, 2024
One of the common indicators of prostate cancer recurrence is an elevated level of prostate-specific antigen (PSA). When PSA levels begin to rise after treatment, it signals that the cancer may be returning, leading to what is known as biochemically recurrent (BCR) prostate cancer. In recent years, the focus has…
Published on August 7, 2024
University of Sheffield scientists have discovered a novel form of immunotherapy that utilizes nanoparticles to activate immune cells to kill cancer cells and delays resistance to powerful first-line treatment. This study in mouse and human prostate tumors could help men with prostate cancer to live longer. The findings are published…
Published on July 24, 2024
Huntsman Cancer Institute researchers have shown that less than a third of patients with metastatic prostate cancer or advanced urothelial carcinoma undergo next-generation sequencing (NGS), even though these tumors may have mutations that could be used to guide treatment. The NGS rates have increased over time, but were lower among…
Published on July 17, 2024
Researchers have known for some time that about seven percent of people diagnosed with low-risk prostate cancer following a biopsy actually have the deadly form of the disease. Recently, some experts have called for the lowest grade of prostate cancer—biopsy Gleason Grade Group (GGG) 1—to be reclassified as “benign.” A…
Published on July 10, 2024
Researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Belgium, have developed a novel liquid biopsy methodology that enables the monitoring of disease evolution in patients with metastatic prostate cancer. The study, published in Cancer Cell, leverages the RNA contained in extracellular vesicles shed by tumor cells into the…
Published on June 14, 2024
An international study led by the Radboud University Medical Center has demonstrated that artificial intelligence (AI) can detect prostate cancer on MRI scans more effectively than radiologists, while also reducing false positives by half. The findings, published in The Lancet Oncology, mark a significant advancement in the use of AI…
Published on June 12, 2024
A first-in-man study, by researchers at the Nuffield department of surgical sciences and the department of oncology, at the University of Oxford, Oxford University Hospitals and Oxford NIHR Biomedical Research Center University of Oxford, and at Oxford University Hospitals NHS Trust, demonstrates how a fluorescent marker dye that sticks to…